CD19-directed CAR therapy shows promise in patients with advanced hematologic malignancies

Study results of CD19-directed chimeric antigen receptor therapy using the Sleeping Beauty non-viral transduction system to modify T cells has demonstrated further promise in patients with advanced hematologic malignancies. Patients who had acute lymphocytic leukemia , non-Hodgkin lymphoma or chronic lymphocytic leukemia were part of clinical trials at The University of Texas MD Anderson Cancer Center, which used the Sleeping Beauty gene transfer system initially discovered at the University of Minnesota.

http://ift.tt/12F0qSt